Case report: Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: Recovery after amphotericin B following failure of oral miltefosine

American Journal of Tropical Medicine and Hygiene

Volumn 79, Issue 5, 2008, Pages 715-718

  Guffanti, Monica ^a   Gaiera, Giovanni ^a   Bossolasco, Simona ^a   Ceserani, Norberto ^a   Ratti, Deborah ^a   Cinque, Paola ^a   Salmaso, Flavia ^b   Gianotti, Nicola ^a   Lazzarin, Adriano ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; AMPHOTERICIN B; ANTIPARASITIC AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; AIDS RELATED COMPLEX; ORAL DRUG ADMINISTRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; NASO HEXACANTHUS;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIPARASITIC AGENTS; FEMALE; HIV-1; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 55849126350     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2008.79.715     Document Type: Article

References (16)

1. Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87-98.
2. Lawn SD, Wilkinson RJ, 2006. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 28: 625-633.
3. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L, 2007. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157: 1032-1036.
4. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
5. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272.
6. TDR 2007. Eighteenth Programme Report/Progress 2005-2006. Available at: www.who.int/tdr. Accessed September 27, 2007.
7. Sindermann H, Engel KR, Fischer C, Bommer W for the Miltefosine Compassionate Use Program, 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39: 1520-1523.
8. Schraner C, Hasse B, Hasse U, Bauman D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF, 2005. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40: e120-e124.
9. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE, 2006. Successful treatment of post-kala-azar-dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 53: e25-e27.
10. Dejenie Belay A, Asafa Y, Mesure J, Davidson RN, 2006. Successful miltefosine treatment of post-kala-azar-dermal leishmaniasis occurring during antiretroviral treatment. Ann Trop Med Parasitol 100: 223-227.
11. Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V, 2006. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 100: 698-700.
12. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P, 2003. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41: 5080-5084.
13. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: 57-61.
14. Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F, 2006. Mechanism of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 9: 26-39.
15. Berman J, Bryceson ADM, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA, 2006. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 100S: S41-S44.
16. Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100S: S17-S20.